Posts

Posted on

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today announced that Everest Medicines (HKEX1952, or “Everest”), has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals (“CORXEL”) to acquire the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China, including Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan region.

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets, with therapeutic areas of focus including ophthalmology, CKM (cardiovascular, kidney, and metabolic), autoimmune and critical care.

The New Drug Application (NDA) for LNZ100 in China was submitted to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People’s Republic of China (PRC) in September 2025, with approval anticipated in Q1 2027. As part of this agreement, Everest will be assigned and transferred the rights and obligations under the LENZ License Agreement entered into by CORXEL in April 2022 and certain related ancillary agreements. LENZ is eligible to receive up to $85.0 million in remaining regulatory and sales milestones, as well as tiered mid single-digit to low double-digit royalties on net sales in Greater China. LENZ is also now eligible to receive additional payments in connection with the execution of the agreement between CORXEL and Everest.

“The acquisition of LNZ100 represents an important step in advancing Everest’s strategic focus in ophthalmology. LNZ100 is a differentiated asset with meaningful clinical value and strong commercial potential in the treatment of presbyopia,” said Yifang Wu, Chairman of the Board of Everest Medicines. “As the presbyopia patient population continues to grow, significant unmet needs remain in non-invasive treatment options. We believe LNZ100 has the potential to offer patients a novel, non-invasive therapeutic option and to further broaden the landscape of innovative ophthalmic treatments. The product has already been approved in the United States and is currently under regulatory review in China. We will continue to advance its development and commercialization to make this therapy accessible to presbyopia patients.”

“We thank the CORXEL team for their partnership in the clinical execution and regulatory stewardship of LNZ100 in China”, said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “We look forward to collaborating with Everest as we approach regulatory approval and commercial launch in China, providing a transformative new treatment option for millions of adults living with presbyopia.”

About LENZ Therapeutics

LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.lenz-tx.com.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of United States federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “poised,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of approval of LNZ100 in Greater China; and plans and expectations regarding the commercialization of LNZ100 in China, if approved. These statements are based on numerous assumptions concerning LENZ, VIZZ, target markets and regulatory agencies and involve substantial risks, uncertainties and other factors that could cause actual results to differ materially from those projected, expressed or implied by these forward-looking statements, including risks related to regulatory approvals, market conditions, and those risk factors described in the section titled “Risk Factors” in our Quarterly Report on Form 10-Q filed for the quarter ended March 31, 2026 and our subsequent filings with the Securities and Exchange Commission. We cannot assure you that the forward-looking statements in this press release or the assumptions upon which they are based will prove to be accurate. The forward-looking statements in this press release are made as of the date of this press release. Except as otherwise required by applicable law, LENZ disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Contact:

Dan Chevallard
LENZ Therapeutics
[email protected]



Posted on

Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Announces Upcoming EAI Robotics Major Launch Events in June, Along with the First Cooperation Agreement with U.S. K-12 Public School

Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Announces Upcoming EAI Robotics Major Launch Events in June, Along with the First Cooperation Agreement with U.S. K-12 Public School

  • FF will hold its FF EAI Robotics Education Ecosystem Strategy, Product Line & New EAI Device Launch at its Los Angeles headquarters on June 16, where the Company will give a full and in-depth introduction to FF’s robotics education ecosystem strategy and also launch its EAI education product line and several major new EAI devices.

  • On June 22, at Automate in Chicago, the largest robotics show in North America, FF will hold the FF EAI Robotics Multi-Form Lineup Debut & New Product Launch. FF will use this event to share more on its Three-in-One EAI ecosystem and EAI device lineup.

LOS ANGELES–(BUSINESS WIRE)–
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today shared a weekly business update from YT Jia, Founder and Global CEO of FF.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607036897/en/

Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Announces Upcoming EAI Robotics Major Launch Events in June, Along with the First Cooperation Agreement with U.S. K-12 Public School

Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Announces Upcoming EAI Robotics Major Launch Events in June, Along with the First Cooperation Agreement with U.S. K-12 Public School

“Hello from issue 58 of our weekly report. This week, I would like to share two key updates with everyone: first, our upcoming major launch events; and second, an important breakthrough in our robotics education ecosystem.

Since we first announced our robotics strategy in February, FF’s EAI robotics business, product development, and industrialization efforts have all been making steady progress. We have also continued to make important breakthroughs in device delivery, real-world use cases, and education ecosystem partnerships. The positive feedback from both B2B customers and B2C users has continued to validate real market demand and a major industry opportunity. The value of FF’s five unique core advantages, including our Global EAI Industry Bridge model, is becoming increasingly clear.

Therefore, in mid-June, we will kick off the launch season for the full multi-form lineup of FF EAI robots. On June 16 5:00 p.m. U.S. time, or 8:00 a.m. Beijing time on June 17, we will hold our FF EAI Robotics Education Ecosystem Strategy, Product Line & New EAI Device Launch at our Los Angeles headquarters. At the event, we will give a full and in-depth introduction to FF’s robotics education ecosystem strategy. We will also launch our EAI education product line and several major new EAI devices. The event will also include guest interviews and hands-on product experiences. We will invite representatives from B2B customers, B2C users, and partners to discuss AI and education. The event will be livestreamed globally, and we welcome all Futurists to tune in.

On June 22, at Automate in Chicago, the largest robotics show in North America, we will hold the FF EAI Robotics Multi-Form Lineup Debut & New Product Launch. This will give the industry a clear and concrete view of FF’s Three-in-One EAI ecosystem and EAI device lineup. We welcome everyone to come check our booth and follow our updates during the event.

Second, we made major progress this week in our education ecosystem partnership with a K–12 public school district. FF AI-Robotics and the Lynwood Unified School District in LA officially signed a strategic cooperation MOU for K–12 robotics education, as well as a formal cooperation agreement for a robotics summer camp.

Together, we plan to launch our first EAI robotics summer camp for K–12 students this summer. The program will include AI learning sessions, hands-on robotics practice, and student project showcases. This is FF’s first strategic cooperation within the U.S. K–12 education system. For us, this is a very important milestone.

This will help accelerate FF’s efforts to build the first scaled EAI education ecosystem in the U.S. and the first AI-native education system. It will also support FF’s goal of becoming a pathbreaker, ecosystem builder, and mass-adoption driver in the global B2C robotics market and its real-world use cases, and also our target of becoming the first robotics education ecosystem trailblazer and driving force serving both B2B educational institutions and B2C family education.

This cooperation is expected to open up two key entry points: K–12 full-time schools on the B2B side, and family education for students on the B2C side. It also creates a repeatable user acquisition model that can drive viral growth across the U.S.

AI is rapidly reshaping education and the skills needed for future careers. Schools and families in the U.S. are both facing new anxiety around AI. FF’s robotic devices, ecosystem products, and solutions are well positioned to meet this need and address the demands and pain points of both B2B and B2C users.

Next, FF and Lynwood will continue to explore broader cooperation with government agencies, school districts, educational institutions, and industry partners. Step by step, we aim to replicate the Lynwood cooperation model across the U.S. education system and the family education market.

On the product and technology side, we have completed the first version of Create Studio, our motion capture and Skill creation tool. It is one of the six developer platform tools we are developing in-house. We are now continuing to optimize it, and it is expected to officially launch soon. With this tool, we expect to significantly lower the barrier to robot motion and Skills creation. It will allow developers of all ages to learn AI and programming more easily, and to create robot movements, dances, performances, teaching interactions, and more.

Kerr and Lerr have received their own FF EAI robots and started their journey as young developers. They have been learning how to use developer tools for Agent and Skills development, and how to train their robots. At the June 16 launch event, Kerr and Lerr will share what they have recently learned and built. I can’t wait to see what they have created.

At the same time, EAI Soul, our robot persona development tool, has also entered internal testing. We have already developed professional personas for use cases such as tech product sales, real estate sales, and financial services. This means FF EAI robots are gradually gaining professional Agent capabilities and specialized service capabilities for real-world business scenarios. This also lays the foundation for the Robot Vocational Academy and for large-scale deployment in vertical use cases. That’s all for this week. See you next time!”

ABOUT FARADAY FUTURE

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a Three-in-One ecosystem of “Device, Data, EAI Brain & Open-Source and Open Platform,” FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future’s official website: https://www.ff.com/

FORWARD LOOKING STATEMENTS

This press release includes “forward looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “plan to,” “can,” “will,” “should,” “future,” “potential,” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding potential future legal actions against alleged illegal market manipulation or similar improper activities, and FF’s entry into the embodied AI robotics market and robotics deliveries and development, involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important factors, that may affect actual results or outcomes include, among others: the Company’s ability to timely regain compliance with Nasdaq’s minimum bid requirement; the Company’s common stock will be suspended from trading on Nasdaq if it’s closing price is $0.10 or less for 10 consecutive trading days; the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations, which it currently lacks; the availability of sufficient share capital to meet its current obligations and execute on its strategy, which the Company currently lacks; the agreement of stockholders to substantially increase the Company’s share capital, which could result in substantial additional dilution; the willingness of convertible debt investors to fund the Company while it lacks sufficient share capital for conversions; demand for the Company’s robotics products; the ability of B2B preorder companies to locate customers to purchase our robotics products, on which their nonbinding preorders substantially depend; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; the Company’s reliance on a single OEM for most of its robotics products; the Company’s ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for imported products, particularly from China; demand from automobile dealers for robotics products; the Company’s ability to homologate FX vehicles for sale; the Company’s ability to secure the necessary funding to execute on the FX strategy, which is substantial; the Company’s ability to secure an occupancy certificate covering all of its Hanford facility; the Company’s ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of substantial losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company’s estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company’s vehicles; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company’s vehicles; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company’s operations in China; the success of the Company’s remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company’s ability to develop and protect its technologies; the Company’s ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company’s stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 14, 2026, and Form 10-K filed with the SEC on March 31, 2026, and other documents filed by the Company from time to time with the SEC.

Investors (English): [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

KEYWORDS: China United States North America Asia Pacific California

INDUSTRY KEYWORDS: Technology Family Robotics Automotive Manufacturing Manufacturing Consumer Training Machinery Artificial Intelligence Other Technology Primary/Secondary Software Education Other Manufacturing

MEDIA:

Photo
Photo
Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Announces Upcoming EAI Robotics Major Launch Events in June, Along with the First Cooperation Agreement with U.S. K-12 Public School
Photo
Photo
Faraday Future will hold its FF EAI Robotics Education Ecosystem Strategy, Product Line & New EAI Device Launch at its Los Angeles headquarters on June 16, where the Company will give a full and in-depth introduction to FF’s robotics education ecosystem strategy and also launch its EAI education product line and several major new EAI devices.
Logo
Logo
Posted on

Odysight.ai® Establishes At-The-Market (ATM) Program of up to $20 Million to Enhance Financial Flexibility

Ramat Gan, Israel, June 07, 2026 (GLOBE NEWSWIRE) — Odysight.ai® (NASDAQ/TASE: ODYS) today announced that, as part of a planned step to expand the Company’s financing toolkit in the U.S. capital market, it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC) under which it may offer and sell from time to time and at its discretion shares of its common stock having an aggregate offering price of up to $20 million pursuant to an At-The-Market (ATM) program with the investment bank Roth Capital Partners. The program provides the Company with an additional, flexible financing infrastructure that can be utilized at the Company’s discretion to support business development and capitalize on market opportunities.

Establishing the ATM program does not obligate the Company to issue or sell any shares, and there can be no assurance that the Company will issue and sell any shares under the ATM program. The Company retains full control over whether, when, at what price, and to what extent the ATM program is used.

This move is designed to provide Odysight.ai with added financial flexibility, enabling the Company to continue advancing its strategic and commercial objectives from a position of stability and for the benefit of all of its stakeholders.

The shares will be offered pursuant to a sales agreement between the Company and Roth Capital Partners, LLC, as sales agent. Sales may be made by any method permitted by law to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including in ordinary brokers’ transactions on the Nasdaq Capital Market at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices, in block transactions, as otherwise agreed with the applicable sales agent, by means of any other existing trading market for the Company’s common stock, to or through a market maker other than on an exchange, or through a combination of any such methods of sale. Sales may be made at market prices prevailing at the time of the sale, at prices related to prevailing market prices or at negotiated prices and, as a result, sales prices may vary.

The prospectus supplement filed on June 5, 2026 adds to, updates or otherwise changes information contained in the accompanying prospectus contained in the Company’s shelf registration statement on Form S-3 (File No. 333-293080) filed by the Company with the SEC on January 30, 2026, and which became effective on February 6, 2026, for the offering of the Company’s securities. Prospective investors should read the prospectus in that registration statement and the prospectus supplement (including the documents incorporated by reference therein) for more complete information about the Company and the ATM program, including the risks associated with investing in the Company’s securities. Copies of the prospectus supplement and related prospectus may be obtained from Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660. You may also obtain these documents free of charge when they are available by visiting EDGAR on the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, solicitation or sale will be made only by means of the prospectus supplement and the accompanying prospectus.

About Odysight.ai

®

Odysight.ai, incorporated in Nevada, U.S., with subsidiaries in Europe and Israel, is advancing the Predictive Maintenance (PdM) and Condition-Based Monitoring (CBM) markets through an AI platform for critical systems across aviation and aerospace, transportation, energy, and industrial sectors. By combining advanced visual sensing, real-time analytics, and AI-driven insights, Odysight.ai helps organizations improve safety, efficiency, and operational intelligence. Its technology has been deployed in projects with NASA, the U.S. Department of Defense, and leading aerospace OEMs, delivering measurable improvements in system reliability and maintenance performance.


See what others miss. Predict what matters most.



www.odysight.ai




https://www.linkedin.com/company/odysightai

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements within the meaning of safe harbor provisions of the Private Securities Litigation Reform Act of 1995 relating to future events or our future performance. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the establishment and potential utilization of the At-The-Market (ATM) program, the Company’s financing plans and financial flexibility, and future applications of the Company’s technology. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Those statements are based on information we have when those statements are made or our management’s current expectation and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that may affect our results, performance, circumstances or achievements include, but are not limited to, the following: (i) our ability to scale up our operations, including market acceptance and large-scale adoption of our vision-based sensor products, (ii) the amount and timing of future sales and our long and unpredictable sales cycles, (iii) our estimates regarding expenses, backlog, future revenue, capital requirements and need for additional financing, (iv) our ability to access the capital markets on acceptable terms or at all, (v) the dilutive impact of any sales of shares under the ATM program, (vi) compliance with existing laws and regulations and regulatory developments in the United States, Israel, and other jurisdictions, (vii) our financial performance and history of operating losses, (viii) the overall global economic environment and trade tensions, including the adoption or expansion of economic sanctions, tariffs or trade restrictions, (ix) security, political and economic instability in the Middle East that could harm our business, including due to the security situation in Israel and military conflicts with Iran and terrorist organizations, (x) the increased expenses and requirements associated with being a listed public company on the Nasdaq Capital Market, or Nasdaq, and (xi) the unknown effect on the price of our common stock of the dual listing of our common stock on the Tel Aviv Stock Exchange, which took place on April 9, 2026. These and other important factors discussed in Odysight.ai’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 19, 2026, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Except as required under applicable securities legislation, Odysight.ai undertakes no obligation to publicly update or revise forward-looking information.

Company Contact:

Einav Brenner, CFO
[email protected]

Investor Relations Contact:

Miri Segal, MS-IR LLC
[email protected]



Posted on

NAVER Expands AI Infrastructure With NVIDIA to Serve Surging Global AI Demand

NAVER to Build NVIDIA DSX-Based AI Factories at Gigawatt Scale to Power Agents and Physical AI

News Summary:

  • NAVER, an AI Cloud, will build AI factories on the NVIDIA DSX platform at gigawatt scale, starting with AI infrastructure expansion at GAK Sejong.
  • NVIDIA DSX gives NAVER a proven AI factory blueprint to serve Korea’s industries and global AI cloud customers as demand for useful AI surges at lowest token cost.
  • NAVER will use NVIDIA full-stack AI platforms, models and software to advance regional AI models including next-generation HyperCLOVA X models, its Seoul World Model development and agentic AI services.

SEOUL, South Korea, June 07, 2026 (GLOBE NEWSWIRE) — NVIDIA and NAVER today announced that NAVER will expand sovereign AI infrastructure, starting at 55 megawatts with plans to move to gigawatt scale using the NVIDIA DSX™ platform to rapidly design, build and scale full-stack, end-to-end AI platforms that can serve enterprises, industries and government.

“Useful AI has arrived, and demand for AI factories is extraordinary,” said Jensen Huang, founder and CEO of NVIDIA. “NAVER is building AI factory infrastructure that will serve its companies, developers and industries. With NVIDIA DSX, we can help Korea scale sovereign intelligence infrastructure for the agentic era — from AI agents to AI factories and physical AI.”

“NAVER is building sovereign AI infrastructure that can serve Korea’s industries and global customers with trusted, high-performance AI,” said Haejin Lee, founder and chairman of NAVER. “By building on the NVIDIA DSX platform, we can help customers move from AI experimentation to production-scale AI factories that power models, agents and real-world services.”

As useful AI increasingly moves to production, AI factories are becoming critical infrastructure for training, post-training and inference. Built with the NVIDIA DSX platform with NVIDIA accelerated computing, NAVER’s AI factories will give Korea a sovereign foundation to create intelligence for enterprises, manufacturers, government organizations and AI cloud customers.

NVIDIA DSX-Powered AI Cloud to Expand NAVER GAK Sejong Data Center

The new DSX-powered cloud will expand NAVER’s GAK Sejong data center, a next-generation, hyperscale facility in Sejong, South Korea, built to power the company’s rapidly growing AI and cloud services.

Designed for high‑density NVIDIA accelerated computing, GAK Sejong delivers resilient, energy‑efficient operations with advanced automation, sustainability features and robust disaster‑response capabilities. GAK Sejong positions NAVER to support large‑scale digital services and innovation across Korea and beyond.

NAVER is serving sovereign AI demand with infrastructure across Europe and the Middle East. By combining its hyperscale data center capabilities with NVIDIA DSX, NAVER aims to offer government and enterprise customers a trusted alternative for secure, high‑performance digital services compliant with local regulatory and data‑sovereignty requirements.

NAVER will use NVIDIA full-stack AI platforms not only to fuel sovereign AI models and agentic AI services but also accelerate its AI data center business.

AI Cloud Infrastructure Builds on Companies’ Model Development Collaboration
The new AI cloud infrastructure builds on NVIDIA and NAVER’s partnership in advancing sovereign and physical AI models in Korea.

NAVER is advancing its HyperCLOVA X models by fine-tuning the NVIDIA Nemotron™ 3 Ultra open model with its proprietary data and training expertise, delivering a more capable and culturally fluent model for Korean and global enterprise customers. HyperCLOVA X models based on NVIDIA Nemotron also provide a platform to support sovereign AI initiatives in Europe and the Middle East.

NAVER is the first Korean company to participate in the NVIDIA Nemotron Coalition, contributing to open model development across pretraining, post-training and reinforcement learning to accelerate global AI innovation. It plans to launch an AI Agent Platform in Korea in the second half of the year, powered by NVIDIA NemoClaw™ blueprints.

NAVER is also developing a Seoul World Model using its proprietary urban street-view data and spatial modeling technology, building on NVIDIA Cosmos™ world foundation models.

NVIDIA DSX Platform to Power Rapid NAVER Expansion

The NVIDIA DSX platform is purpose-built as an end‑to‑end, codesigned stack for AI factories, spanning chips, systems, software, facilities and partner technologies to minimize token cost and speed time to first production.

NVIDIA DSX platform will pair with NAVER’s expertise in building and operating large-scale proprietary GPU clusters and hyperscale data centers.

NVIDIA DSX MaxLPS™ software achieves the lowest token cost by maximizing token throughput per megawatt, while NVIDIA DSX OS™ provides the operating layer that enables providers to grow revenue and enhance margins through open source, modular software for lifecycle management, consistent runtime operations, health automation, resiliency and multi‑tenant AI factory management.

About NAVER

NAVER Corporation has been providing internet services and IT infrastructure since 1999, growing into one of Asia’s leading technology companies. With over two decades of operational excellence powering its own platforms and affiliates, NAVER delivers enterprise-grade digital solutions through NAVER Cloud Platform — its public cloud service built on proven, large-scale infrastructure.

NAVER is the world’s third company to develop a hyperscale Large Language Model, reflecting its deep investment in cutting-edge AI research and development. Leveraging this advanced AI expertise, NAVER offers end-to-end capabilities across the entire AI value chain — encompassing AI services, data, foundational AI infrastructure, supercomputing resources, cloud platforms, and data centers — to support businesses navigating digital transformation.

About NVIDIA


NVIDIA
 (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:

Corporate Communications
NVIDIA Corporation
[email protected]  

Certain statements in this press release including, but not limited to, statements as to: NAVER Cloud building AI factory infrastructure that will serve its companies, developers and industries; with NVIDIA DSX, NVIDIA being able to help Korea scale sovereign intelligence infrastructure for the agentic era — from AI agents to AI factories and physical AI; expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments, and related trends and drivers; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, DSX MaxLPS, DSX OS, NemoClaw, Nemotron, NVIDIA Cosmos and NVIDIA DSX are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and/or other countries. Other company and product names may be trademarks of the respective companies with which they are associated.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bae0b9ac-5f9e-470f-99d2-5a5b836da3f2



Posted on

NVIDIA and SK hynix Announce Multiyear Technology Partnership to Advance Memory for AI Factories

Collaboration Supports Next-Generation Memory Codevelopment With NVIDIA’s AI Infrastructure Roadmap and Expands Supply for the Accelerating Global AI Factory Buildout

News Summary:

  • NVIDIA and SK hynix announce multiyear technology partnership for next-generation memory aligned to NVIDIA’s AI infrastructure roadmap.
  • The agreement supports supply for advanced memory, addressing the extended development cycles, advanced fabrication and capital investments to sustain the global buildout of AI factories.
  • SK hynix will diversify into new markets NVIDIA is creating — across AI infrastructure, personal AI and physical AI — codeveloping memory for NVIDIA Vera Rubin AI supercomputers, Vera CPUs, RTX Spark-powered PCs and Jetson Thor robotic computing platforms.
  • The two companies will apply AI to semiconductor chip design and manufacturing, using NVIDIA CUDA-X libraries and NVIDIA PhysicsNeMo to accelerate semiconductor simulations, TCAD workflows and in-house engineering codes.
  • SK hynix will advance factory digital twins by combining NVIDIA Omniverse, OpenUSD scene optimization and NVIDIA cuOpt to drive fully autonomous fab operations.


SEOUL, South Korea, June 07, 2026 (GLOBE NEWSWIRE) — NVIDIA and SK hynix today announced a multiyear technology partnership to advance next-generation memory for the global AI factory buildout and accelerate semiconductor design and manufacturing. The agreement builds on years of deep co-engineering collaboration that has powered some of the world’s most advanced AI computing platforms.  

“AI factories are the engines of the next industrial revolution, and advanced memory is essential to their performance,” said Jensen Huang, founder and CEO of NVIDIA. “SK hynix has been an extraordinary partner to NVIDIA, playing a central role in delivering advanced memory technologies for NVIDIA AI computing platforms. Together, we will codevelop the next generation of memory for AI factories and support the accelerating global expansion of AI infrastructure — from frontier model training to agentic and physical AI.”

“SK hynix and NVIDIA have been building toward this for years, and this partnership reflects the depth of that collaboration,” said Chey Tae-won, Chairman of SK Group. “Together, we are codeveloping the next generation of memory for AI factories and applying AI to how we design and manufacture semiconductors — work that will shape the future of AI infrastructure.”

The multiyear agreement supports supply to address the extended development cycles of advanced memory. As AI factories scale globally, this strategic partnership enables memory supply to keep pace with NVIDIA’s infrastructure roadmap and the sustained buildout of AI infrastructure worldwide. Through this partnership, SK hynix will diversify into new markets NVIDIA is creating — spanning AI infrastructure, personal AI and physical AI — codeveloping memory for NVIDIA Vera Rubin AI supercomputers, NVIDIA Vera CPUs, NVIDIA RTX Spark™-powered PCs and NVIDIA Jetson Thor™ robotic computing platforms.

Accelerating Technology Computer-Aided Design and Semiconductor Simulation

SK hynix is using NVIDIA CUDA-X™ libraries and AI to speed semiconductor simulation, including technology computer-aided design and computational lithography workflows.

SK hynix is also using CUDA-X and the NVIDIA PhysicsNeMo™ framework to deliver core-workload acceleration across its in-house simulation codes and AI physics workflows.

By extending these tools to the semiconductor electronic design automation and simulation ecosystems, this initiative paves the way for three-way collaborations among chipmakers, NVIDIA and electronic design automation software vendors.

Advancing Fab Digital Twins for Autonomous Manufacturing

SK hynix is developing fab digital twins as a foundation for autonomous fab operations. Teams can use scene optimization technologies, as well as NVIDIA Omniverse™ libraries and OpenUSD pipelines, to build 3D factory scenes for visualizing, simulating and optimizing complex semiconductor manufacturing environments.

These digital twins can also support operational optimization, including the movement of autonomous mobile robots and other fab assets, using the open source, GPU-accelerated NVIDIA cuOpt™ decision optimization engine and the NVIDIA Metropolis platform.

The companies are also exploring ways to connect digital twins with existing legacy software and agentic AI workflows, enabling AI systems to reason over fab data, automate tasks and improve manufacturing decision-making.

About SK hynix Inc.

SK hynix Inc., headquartered in Korea, is the world’s top tier semiconductor supplier offering Dynamic Random Access Memory chips (“DRAM”) and flash memory chips (“NAND flash”) for a wide range of distinguished customers globally. The Company’s shares are traded on the Korea Exchange, and the Global Depository shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.

About NVIDIA

NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:

Corporate Communications
NVIDIA Corporation
[email protected] 

SK hynix Inc.
Global Public Relations
[email protected]

Certain statements in this press release including, but not limited to, statements as to: SK hynix and NVIDIA codeveloping the next generation of memory for AI factories and support the accelerating global expansion of AI infrastructure — from frontier model training to agentic and physical AI; expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments, and related trends and drivers; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, CUDA-X, cuOpt, Jetson Thor, NVIDIA PhysicsNeMo and NVIDIA RTX Spark are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and/or other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c5f282c7-54c2-40b0-99fe-c1f525f88ee7



Posted on

SK Telecom and NVIDIA Build AI Infrastructure to Power Korea’s AI Innovation

Korea’s Leading Telco to Add NVIDIA-Powered AI Cloud Capacity Built on NVIDIA DSX AI Factory Architecture to Accelerate AI Startups, Robotics and Industrial Physical AI

News Summary:

  • SK Telecom plans to build a gigawatt-scale AI Cloud in Korea using the NVIDIA DSX platform, with the first AI factory planned to come online in 2027.
  • The AI Cloud will support sovereign, physical and agentic AI services for enterprises and industries across Korea, building on SK Telecom’s network, data center and enterprise infrastructure expertise.
  • NVIDIA DSX will serve as the AI factory architecture blueprint, combining NVIDIA accelerated computing, systems, software and partner technologies to improve time to production and token performance per megawatt.
  • NVIDIA and SK Group are planning to expand their collaboration from AI infrastructure deployments to joint research on next-generation AI factory architectures.

SEOUL, South Korea, June 07, 2026 (GLOBE NEWSWIRE) — NVIDIA and SK Telecom today announced that SK Telecom plans to build a gigawatt-scale AI Cloud in Korea using the NVIDIA DSX™ platform, with the first AI factory coming online in 2027.

An AI Cloud is large-scale AI infrastructure comprised of AI factories that manufacture tokens, building blocks of intelligence, from data. Unlike conventional large-scale providers offering general-purpose cloud services, AI Clouds specialize in GPU-based cloud computing tailored specifically for AI workloads across training, inference and agentic AI.

SK Telecom’s AI Cloud will be built on the NVIDIA DSX full-stack reference architecture of software, hardware and operations producing the lowest-cost tokens at maximum energy efficiency.

SK Telecom’s AI Cloud will power training, inference and agentic workloads including sovereign, physical and enterprise AI services for companies and industries across Korea, with the vision to expand to greater Asia regions.

The initiative reflects Korea’s role as one of the world’s most advanced pro-AI industrial economies. Korean companies lead in telecommunications, memory, semiconductors, manufacturing, robotics, mobility and consumer technology — industries where AI is moving from research labs and chatbots into secure, production-grade deployments.

“Telecom networks are becoming national AI infrastructure,” said Jensen Huang, founder and CEO of NVIDIA. “They connect people, companies, devices and machines — and now they can become the backbone of new AI clouds. With NVIDIA DSX, SK Telecom can build Korea’s AI cloud at scale and bring agents, enterprise and physical AI to the companies and industries that power Korea and the world.”

“Through our close partnership with NVIDIA, we have now secured full-stack AI infrastructure capabilities, from chips to data center operations,” said Chey Tae-won, Chairman of SK Group. “We will work with NVIDIA to tackle GPU, memory and energy challenges and become a leading AI factory player shaping Asia’s AI ecosystem.”

SK Telecom AI Cloud to Scale Agentic and Physical AI for Industries and Enterprises

The new SK Telecom AI Cloud is designed to serve rising demand for AI infrastructure, as accelerated AI computing growth continues to increase.

The new infrastructure builds on SK Telecom’s leadership in physical AI and agentic AI development. At GTC Taipei last week, SK Telecom announced its latest work in applying digital twins to SK hynix semiconductor fabs using NVIDIA Omniverse™ libraries, optimizing the technology for complex, large-scale manufacturing environments.

In April, SK Telecom revealed that it has adopted open source NVIDIA Nemotron™ datasets to train the A.X K1 model as part of the Korea government’s Sovereign AI Foundation Model Project.

Moreover, as part of this collaboration, SKT will become an NVIDIA Cloud Partner, joining a global program through which participants use NVIDIA’s latest AI infrastructure, software and developer ecosystem to deliver excellent AI performance and economics through AI cloud services.

NVIDIA DSX Platform Delivers Rapid Design, Ultraefficient Operations

The NVIDIA DSX platform is engineered from the ground up with extreme codesign for AI factories, built and operated to drive lowest token cost and accelerate time to first production across NVIDIA chips, systems, software, facilities and partner technologies.

NVIDIA DSX MaxLPS™ software delivers the lowest token cost by maximizing token performance per megawatt. NVIDIA DSX OS™ is the operating layer that helps providers increase revenue and improve margins with open source, modular software for lifecycle management, runtime consistency, health automation, resiliency and multi-tenant AI factory operations.

NVIDIA and SK Group to Pursue Joint Research for Next-Gen AI Infrastructure

NVIDIA and SK Group today announced plans to pursue joint research to codevelop next-generation AI factory architecture, extending their collaboration beyond infrastructure deployment.

The companies will focus on silicon-to-grid innovation across accelerated computing, memory technologies and data center operations. NVIDIA and SK Group companies including SKT will also explore projects for full-stack AI factory optimization to drive more efficient, scalable and resilient AI services.

About NVIDIA


NVIDIA
 (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:

Corporate Communications
NVIDIA Corporation
[email protected]  

Certain statements in this press release including, but not limited to, statements as to: telecom networks becoming the backbone of AI clouds; with NVIDIA DSX, SK Telecom being able to build Korea’s sovereign AI cloud at scale and bring agents, AI factories and physical AI to the enterprises and industries that power Korea and the world; expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments, and related trends and drivers; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, DSX OS, DSX MaxLPS, NVIDIA DSX, NVIDIA Nemotron and NVIDIA Omniverse are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and/or other countries. Other company and product names may be trademarks of the respective companies with which they are associated.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7211c46b-c2a3-4d5d-b4d8-488f24a081ae



Posted on

VolitionRx Announces Pricing of $4.6 Million Public Offering

PR Newswire


$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants

HENDERSON, Nev., June 7, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common stock, and warrants to purchase up to an aggregate of 1,480,000 shares of common stock, at a combined public offering price of $1.55 per share and accompanying half warrant. Each warrant will have an exercise price of $1.55 per share, will be exercisable immediately upon issuance, and will expire five years after the date of issuance. The offering included participation from both new and existing investors.

Maxim Group LLC is acting as the sole placement agent in connection with the offering.

The gross proceeds for the offering are expected to be approximately $4.6 million before deducting placement agent fees and other offering expenses and excluding the proceeds from the exercise of any warrants. The additional gross proceeds to the Company from the exercise of the warrants, if fully-exercised on a cash basis, will be approximately $2.3 million.  However, no assurance can be given that any of the warrants will be exercised.

The offering is expected to close on June 9, 2026, subject to the satisfaction of customary closing conditions.

The securities in the offering are being offered by Volition pursuant to an effective shelf registration statement on Form S-3 (File No. 333-283088), initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 8, 2024, as amended, and declared effective on April 18, 2025. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying base prospectus relating to and describing the terms of the public offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and an accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus, and when filed, the final prospectus supplement and accompanying base prospectus, relating to the public offering may also be obtained by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. 

The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries:

Louise Batchelor, Volition, [email protected], +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements reflect the current belief and expectations of management and relate to, among other topics, statements regarding the expected completion, timing and gross proceeds of the offering. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Volition believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are subject to risks and uncertainties that may cause Volition’s actual activities or results to differ materially from those indicated or implied by any forward- looking statement, including, without limitation, due to risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering, risks disclosed in the section titled “Risk Factors” included in the preliminary prospectus supplement filed with the SEC on June 5, 2026, and risks disclosed in other documents Volition files from time to time with the SEC, including Volition’s Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Cision View original content:https://www.prnewswire.com/news-releases/volitionrx-announces-pricing-of-4-6-million-public-offering-302793460.html

SOURCE VolitionRx Limited

Posted on

FSK Investors Have Opportunity to Lead FS KKR Capital Corp. Securities Fraud Lawsuit

PR Newswire

NEW YORK, June 7, 2026 /PRNewswire/ —

Rosen Law Firm Logo

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of FS KKR Capital Corp. (NYSE: FSK) between May 8, 2024 and February 25, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.

So what: If you purchased FS KKR Capital securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the FS KKR Capital class action, go to https://rosenlegal.com/submit-form/?case_id=64089 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) FS KKR Capital overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) FS KKR Capital overstated the valuation of its portfolio investments and/or overstated the effectiveness of FS KKR Capital’s portfolio valuation process; (3) FS KKR Capital overstated the durability of its quarterly distribution strategy; and (4) as a result of the foregoing, defendants’ positive statements about FS KKR Capital’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the FS KKR Capital class action, go to https://rosenlegal.com/submit-form/?case_id=64089 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fsk-investors-have-opportunity-to-lead-fs-kkr-capital-corp-securities-fraud-lawsuit-302793017.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

PR Newswire

VESALIUS-CV Subgroup Results Show Repatha
®
Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes

New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care

THOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes.

The data include new Phase 3 VESALIUS-CV subgroup results for Repatha® in patients with high-risk diabetes (microvascular disease, insulin use or diabetic duration ≥10 years) and elevated LDL-C (“bad” cholesterol) without prior heart attack or stroke. Results from the analysis of 6,002 patients demonstrate that Repatha, when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, reduced the risk of the composite primary endpoint of coronary heart disease death, myocardial infarction or ischemic stroke (3-P MACE) by 29% compared with placebo.

Repatha also reduced the risk of a second composite primary endpoint that included ischemia-driven revascularization (4-P MACE) by 21%. The median achieved LDL-C was 45 mg/dL in the Repatha arm compared to 106 mg/dL with placebo (898 patients in the subgroup were part of a lipid sub-study).

Approximately one-third and one-fifth of patients were on a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist, respectively, at some point during the study. Similar benefits were observed with Repatha regardless of whether patients were treated with these therapies, highlighting the importance of managing multiple risk factors in patients with high-risk diabetes, including treating uncontrolled LDL-C with Repatha.

“People with diabetes face double the risk of heart attack or stroke compared to those without the condition. These VESALIUS-CV results show that early, intensive LDL-C reduction to 45 mg/dL with Repatha is critical to help prevent life-altering cardiovascular events in those with high-risk disease,” said Jay Bradner, M.D., executive vice president, Research and Development, Artificial Intelligence and Data at Amgen. “Cardiometabolic conditions like elevated LDL-C and diabetes often coexist, compounding risk and leading to adverse outcomes. In addition to these data, Amgen is presenting real-world evidence that underscores the pressing need for continued long-term treatment to realize the full benefit of medical therapy for chronic conditions like diabetes, obesity and cardiovascular disease.”

Amgen presented multiple real-world evidence studies showing that while GLP-1 therapies can provide meaningful improvements in glycemic control and body weight, these benefits are closely tied to sustained treatment use. Across studies, persistence and adherence remained low in routine clinical practice, with many patients discontinuing treatment within the first year, potentially limiting the ability to achieve guideline-recommended HbA1c and weight goals and contributing to more modest outcomes than those seen in clinical trials. These findings highlight an important need for new treatment approaches and care strategies that may help patients stay on therapy longer and realize the full potential benefits of GLP-1 medicines.

Key Amgen presentations during ADA 2026:

Repatha (evolocumab) and LDL-C

  • Evolocumab Reduces CV Events in Patients with High-Risk Diabetes: Results from the VESALIUS-CV Trial
    Abstract #1247-OR, Sunday, June 7 from 3:45 – 4:00 p.m. CDT
    These data were simultaneously published in Diabetes Care.

  • Lipid Management in Patients with High-Risk Diabetes Mellitus at Risk for a First Major Atherosclerotic Cardiovascular Event: Findings from the VESALIUS-REAL Global Study
    Abstract #1448-P, Monday, June 8 from 12:30 – 1:30 p.m. CDT

Obesity

  • Real-World HbA1c and Weight Change 6 and 12 Months by GLP-1 Treatment Persistence in Adults with Type 2 Diabetes

    Abstract #1665-P, Presented Sunday, June 7

  • Impact of GLP-1–Based Treatment Discontinuation on Weight Loss and Glycemic Goals Among Patients with Type 2 Diabetes: Quantifying an Opportunity to Improve Treatment Benefits

    Abstract #1706-P, Presented Sunday, June 7

  • A Meta-Analysis of Persistence and Adherence to Glucagon-Like Peptide-1-Based Treatments Among Patients with Type 2 Diabetes in the United States

    Abstract #1691-P, Presented Sunday, June 7

  • A Meta-Analysis of Real-World Effectiveness of Glucagon-Like Peptide-1s Among Patients with Type 2 Diabetes in the United States

    Abstract #20-PUB, Publication

About the VESALIUS-CV Trial
VESALIUS-CV is a Phase 3, double-blind, randomized, placebo-controlled, global clinical trial designed to evaluate the impact of LDL-C lowering with evolocumab on MACE in adults at high CV risk without prior heart attack or stroke. Results were published in the New England Journal of Medicine in November 2025. Repatha demonstrated a 25% relative reduction in the risk of a composite of coronary heart disease (CHD) death, heart attack or ischemic stroke (3-P MACE), and 19% reduction in a broader composite that also included any ischemia-driven arterial revascularization (4-P MACE). Repatha also reduced the risk of heart attack by 36%.

VESALIUS-CV enrolled more than 12,000 patients with known ASCVD or high-risk diabetes, who had no history of heart attack or stroke, an LDL-C ≥ 90 mg/dL, or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 120 mg/dL, or apolipoprotein B ≥ 80 mg/dL; and treated with highest tolerated dose of statin and/or ezetimibe. The median baseline LDL-C was 122 mg/dL (IQR, 104-149 mg/dL) on local lab testing. Participants were randomized to receive Repatha or placebo in addition to optimized lipid-lowering therapy and were followed for a median of approximately 4.6 years.

Amgen’s Commitment to Cardiometabolic Innovation
Amgen is redefining cardiometabolic care with cutting-edge science rooted in human biology that addresses closely connected cardiovascular and metabolic diseases that lead to serious outcomes or death.

Cardiometabolic conditions commonly coexist and can lead to serious outcomes or death, even though they are treatable.1 Despite advances in lipid-lowering and metabolic therapies, substantial residual cardiovascular risk remains, driven by persistent LDL-C elevation, genetically mediated Lp(a) and obesity-related cardiometabolic dysfunction.2

Leveraging 40+ years of cutting-edge science and human genetics, Amgen is redefining cardiometabolic care and risk management. With years of success in cardiovascular disease with Repatha, Amgen is well positioned to deliver potential breakthrough medicines like MariTide and olpasiran to help address patient needs in cardiometabolic care and multiple interconnected drivers of cardiovascular and metabolic disease.

About Repatha
Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.

Repatha is one of the most extensively studied PCSK9 inhibitors, with clinical and real-world evidence across diverse populations and CV risk profiles.3 The clinical benefits and safety of Repatha have been studied for 15 years in 51 clinical trials with over 57,000 patients.4 Repatha is the only PCSK9 inhibitor to demonstrate a significant reduction of cardiovascular events as both high-risk primary and secondary prevention, with patients achieving and maintain dramatic LDL-C reductions using Repatha only once every two weeks.5,6

Repatha was first approved in 2015 and has since been used by more than 8 million patients globally.7,8 In August 2025, the U.S. Food and Drug Administration broadened the approved use of Repatha to include adults at increased risk for major adverse CV events due to uncontrolled LDL-C. Repatha is approved in 74 countries, including the U.S., Japan, Canada and in all 28 countries that are members of the European Union.9 Applications in other countries are pending.


INDICATIONS


 Repatha® is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.
  • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in:
    • adults with hypercholesterolemia.
    • adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
    • adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).

The safety and effectiveness of Repatha® have not been established in pediatric patients with HeFH or HoFH who are younger than 10 years old or in pediatric patients with other types of hypercholesterolemia. For full prescribing information, visit www.Repatha.com.

 IMPORTANT SAFETY INFORMATION

  • Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

  • Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

  • Adverse Reactions in Adults with Primary Hypercholesterolemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

    From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%). 

  • Adverse Reactions in the FOURIER Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

    Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo. 

  • Adverse Reactions in Pediatric Patients with HeFH: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, headache, oropharyngeal pain, influenza, and upper respiratory tract infection.

  • Adverse Reactions in Adults and Pediatric Patients with HoFH: In a 12-week study in 49 patients, the adverse reactions that occurred in at least two patients treated with Repatha® and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis. In an open-label extension study in 106 patients, including 14 pediatric patients, no new adverse reactions were observed.

  • Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see full Prescribing Information. 

About Obesity

Obesity is a complex chronic disease influenced by genetic, behavioral and environmental factors, that increases the risk of many other serious related diseases and conditions, including type 2 diabetes, heart failure, sleep apnea, and cardiovascular disease.10,11 The worldwide prevalence of obesity more than doubled between 1990 and 2022.12 In the U.S., more than two in five adults (40.3%) are living with obesity.13 Globally, 1 billion people are living with obesity.14

Obesity is linked to a marked reduction in quality of life and an array of serious medical complications and conditions.15,16 Though leading medical organizations, including the American Medical Association and the European Health Commission, recognize obesity as a chronic disease, only 1%-3% of eligible adults in the U.S. are prescribed medication for chronic weight management.17,18,19

For more information about Amgen’s approach to addressing obesity and related conditions, visit https://www.amgen.com/obesity.

About Amgen 
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions.

Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.

Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon’s business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

CONTACT: Amgen, Thousand Oaks
Madison Howard, 773-636-4910 (media)
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors) 

REFERENCES

  1. Eroglu T, Capone F, Schiattarella GG. The evolving landscape of cardiometabolic diseases. EBioMedicine. 2024 Nov;109:105447. doi: 10.1016/j.ebiom.2024.105447. Epub 2024 Nov 4. PMID: 39500010; PMCID: PMC11570325. 
  2. Tan SH, Wu JL, Zhuo SX, Zhang Y, Wang M. Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies. World J Cardiol. 2026 Feb 26;18(2):114960. doi: 10.4330/wjc.v18.i2.114960. PMID: 41694036; PMCID: PMC12897005.
  3. Data on File; Amgen, 2025.
  4. Data on File; Amgen, 2025.
  5. Ndumele, C. E., & Blumenthal, R. S. (2025). VESALIUS and the Anatomy of High-Risk Prevention. New England Journal of Medicine. https://doi.org/10.1056/nejme2515447
  6. Marston, N. A., Bohula, E. A., Bhatia, A. K., et al. (2026). Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: Results from the VESALIUS‑CV trial. JAMA. https://doi.org/10.1001/jama.2026.3277
  7. Shapiro MD. Circulation. 2022;146(15):1120-1122. 
  8. Rao SV, O’Donoghue ML, Ruel M, et al. Circulation. 2025;151(13):e771-e862.
  9. Data on File. Amgen, 2025.
  10. Singh V, Sun J, Cheng S, Kwan AC, Velazquez A. Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization. Adv Ther. 2025;42(11):5341-5364.
  11. Health Risks of Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/health-risks. Published May 2023. Accessed April 27, 2026.
  12. World Health Organization. Obesity and overweight fact sheet. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Updated March 1, 2024. Accessed May 14, 2026.
  13. Fryar CD, Afful J, Saif NT. Prevalence of overweight, obesity, and severe obesity among adults age 20 and over: United States, 1960–1962 through August 2021-August 2023. NCHS Health E-Stat. 2026 Feb;(111):1–7.
  14. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024 Mar 16;403(10431):1027-1050.
  15. Centers for Disease Control and Prevention. Consequences of Obesity. https://www.cdc.gov/obesity/basics/consequences.html. Accessed November 12, 2024.
  16. Hecker J, Freijer K, Hiligsmann M, Evers SMAA. Burden of disease study of overweight and obesity; the societal impact in terms of cost-of-illness and health-related quality of life. BMC Public Health. 2022;22:46.
  17. Burki T. European Commission classifies obesity as a chronic disease. Lancet Diabetes Endocrinol. 2021;9(7):[418].
  18. American Medical Association House of Delegates, 2013. Recognition of obesity as a disease. Resolution 420 (A-13). May 16, 2013. Chicago, USA.
  19. Kim C, Ross JS, Jastreboff AM, et al. JAMA. 2025;333(24):2203–2206.

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-presents-new-data-across-its-cardiometabolic-portfolio-at-american-diabetes-association-86th-scientific-sessions-302793408.html

SOURCE Amgen

Posted on

GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders

Initiates voluntary prepackaged Chapter 11 process to implement Restructuring Transactions that have the support of 100% of its lenders, over 60% of the holders of GoHealth, Inc. Class A Common Stock, and over 99% of the holders of GoHealth Holdings, LLC interests.

Plans to continue operations without interruption and it is business-as-usual for the Company in providing service for existing Medicare consumers and partners.

CHICAGO, June 07, 2026 (GLOBE NEWSWIRE) — GoHealth, Inc. (“GoHealth” or the “Company”), a health insurance marketplace and Medicare-focused digital health company, announced that GoHealth and certain of its subsidiaries have voluntarily filed chapter 11 petitions (the “Chapter 11 Cases”) with the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) to implement the transactions set forth in the Joint Prepackaged Chapter 11 Plan of GoHealth, Inc. and Its Debtor Affiliates Docket No. 4 (the “Plan”). The Plan will transition ownership of the Company to certain of GoHealth’s lenders, reinstate the preferred equity of GoHealth, Inc., provide for payment in full of trade payables and other ordinary course obligations, provide a cash payment to holders of GoHealth common equity, protect GoHealth’s critical relationships with customers and health insurance carriers, and position GoHealth for future success.

GoHealth has already received votes in favor of the Plan from 100% of its lenders, over 60% of the holders of GoHealth, Inc. Class A Common Stock, and over 99% of the holders of GoHealth Holdings, LLC interests. While GoHealth believes these votes are sufficient for the Bankruptcy Court to confirm the Plan under the applicable requirements of the United States Bankruptcy Code, GoHealth anticipates that additional equityholders may vote to accept the Plan in the coming weeks.

GoHealth expects to proceed through the restructuring process quickly and efficiently given the significant support for its prepackaged Plan, with the expectation that it will emerge before the start of the 2026 annual enrollment period (“AEP”).

“The steps we are taking today will provide GoHealth with new owners and a strong financial foundation. This restructuring will enable the Company to continue driving innovation to support Medicare consumers as they assess their current coverage and service needs, with agility and excellence, and to ensure personalized service with differentiated quality,” said Vijay Kotte, Chief Executive Officer of GoHealth. “We plan to continue operations without interruption and believe the support of our key financial partners demonstrates their confidence in our business and the opportunities ahead. We thank our customers, suppliers and business partners for their ongoing partnership and support, and our employees for their continued hard work and dedication. We believe that we will emerge from this process well positioned and look forward to further securing and serving our current members, driving cutting-edge innovation, and bolstering the integral role we play in the consumer value chain.”

Additional Information

Under the Plan, the Company intends to continue operating in the ordinary course during the pendency of the Chapter 11 Cases and to pay vendors, suppliers, and certain other business partners in full for goods received and services provided before and after the Petition Date. To do so, GoHealth has filed a number of customary motions with the Bankruptcy Court, seeking authority to maintain uninterrupted operations and uphold its current and future commitments to employees, vendors, suppliers, customers, and various other stakeholders. Additionally, in connection with the Chapter 11 Cases, the Company expects that (i) the Class A common stock will be delisted from The Nasdaq Global Market and (ii) trading of the Class A common stock thereon will be suspended and following the suspension thereof, the Class A common stock may be quoted on the OTCID Basic Market or another over-the-counter market.

If you would like to obtain a copy of any of the Bankruptcy Court filings and other information related to the proceedings, you should contact Donlin, Recano & Company, LLC, the claims and noticing agent retained by the Debtors in the Chapter 11 Cases by: (a) writing via first class mail, to Donlin, Recano & Company, LLC, c/o Angeion Group, 200 Vesey Street, 24th Floor, New York, NY 10281; (b) writing via electronic mail to [email protected]; or (c) calling the Debtors’ restructuring hotline at +1-877-583-1578 (U.S./Canada, toll-free) or +1-332-284-1398 (International, toll). You may also obtain copies of any pleadings filed in the Chapter 11 Cases (i) for a fee via PACER at https://www.deb.uscourts.gov or (ii) at no charge from Donlin, Recano & Company, LLC by accessing the Debtors’ restructuring website at https://www.bankruptcy.angeiongroup.com/gohealth.

Advisors

Kirkland and Ellis LLP is serving as legal counsel and Alvarez & Marsal North America, LLC is serving as restructuring advisor to GoHealth in connection with these Chapter 11 Cases.

About GoHealth, Inc.

GoHealth is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers’ peace of mind when making healthcare decisions so they can focus on living life. For many of these consumers, enrolling in a health insurance plan is confusing and difficult, and seemingly small differences between health plans may lead to significant out-of-pocket costs or lack of access to critical providers and medicines. GoHealth’s proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer’s specific needs. Its unbiased, technology-driven marketplace coupled with highly skilled licensed agents has facilitated the enrollment of millions of consumers in Medicare plans since GoHealth’s inception.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made in reliance upon the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding approval from the Bankruptcy Court with respect to motions or other requests expected to be made throughout the course of the Chapter 11 Cases, including confirmation of the Plan; the timing and implementation of the transactions contemplated by the Disclosure Statement and the Plan; the effects of the Chapter 11 Cases on the Company and its various constituents, including vendors, suppliers, customers, health plans, brokers, employees and other business counterparties; the Company’s ability to continue operating in the ordinary course, including continuing to serve customers and pay employees, vendors, suppliers and customers in the ordinary course or in the form of reinstatement of trade payables and other ordinary course obligations; the Company’s ability to obtain additional votes from equityholders in support of the Plan and the Company’s belief regarding the sufficiency of such support to satisfy the applicable requirements for acceptance of the Plan under the United States Bankruptcy Code; the potential benefits of the transactions contemplated by the Plan; the Company’s expectation that the Class A common stock will be delisted and that trading will be suspended immediately; and the potential effects of such transactions on the Company’s financial position, capital structure, outstanding debt, interest expense and business are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “likely,” “future” or “continue” or the negative of these terms or other similar expressions although not all forward-looking statements contain these identifying words. The forward-looking statements in this press release are only predictions, projections and other statements about future events that are based on current expectations and assumptions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future events or performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

These forward-looking statements involve risks and uncertainties, both known and unknown, that may cause the Company’s actual results to differ materially from those indicated in the forward-looking statements. Factors that could cause actual future events to differ materially from the forward-looking statements in this press release include, but are not limited to: our ability to continue as a going concern; our ability to continue our business operations following the commencement of the Chapter 11 Cases; the Company’s ability to obtain approval from the Bankruptcy Court with respect to motions or other requests made to the Bankruptcy Court throughout the course of the Chapter 11 Cases, including confirmation of the Plan; the Company’s ability to confirm and consummate the Plan and complete the restructuring on the terms and timeline currently contemplated or at all, and the Company’s ability to realize the intended benefits of the restructuring; our ability to obtain votes from additional equityholders in support of the Plan; the effects of the Chapter 11 Cases on the Company and its various constituents, including vendors, suppliers, customers, health plans, brokers, employees and other business counterparties and including whether ordinary course obligations are paid in full for trade payables and other ordinary course obligations; the length of time the Company will operate under the Chapter 11 process and the supervision of the Bankruptcy Court; the effects of the Chapter 11 Cases on the Company’s liquidity, cash flows, access to financing, financial condition and results of operations; the delisting of the Company’s Class A common stock from Nasdaq and the quotation or trading of the Class A common stock on the over-the-counter market during the pendency of the Chapter 11 Cases; the cancellation of the Company’s and GoHealth Holdings, LLC’s existing equity interests (other than the Series A redeemable convertible preferred stock) pursuant to the Plan, with existing holders of Class A common stock and limited liability units of GoHealth Holdings, LLC receiving limited recovery; the risk that, if the Plan is confirmed and consummated as contemplated, the restructuring will result in a change of control of the reorganized company and existing equity holders (other than the Series A redeemable convertible preferred stock) will lose their ownership, voting and other rights and interests in the Company and GoHealth Holdings, LLC; risks related to the Company’s indebtedness; employee attrition and the Company’s ability to retain senior management and other key personnel, including due to distractions and uncertainties related to the Chapter 11 process; whether the Company’s vendors, suppliers, customers, health plans, brokers and other business counterparties might lose confidence in the Company’s ability to reorganize its capital structure successfully and seek to establish alternative commercial relationships; the diversion of management’s attention as a result of the Chapter 11 Cases; increased administrative and legal costs related to the Chapter 11 Cases; and objections to, or other actions that may delay or prevent confirmation or consummation of, the Plan by creditors, equity holders, regulators or other parties in interest.

These forward-looking statements speak only as of the date of this press release and are subject to a number of additional important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other filings the Company has made or will make with the Securities and Exchange Commission including any of the Company’s Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. You should read this press release and the documents that we reference herein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Media Inquiries

[email protected]